Last reviewed · How we verify
Mifamurtide arm
Mifamurtide arm is a Small molecule drug developed by Italian Sarcoma Group. It is currently in Phase 2 development. Also known as: Methotrexate, Cisplatinum, doxorubicin, ifosfamide.
Mifamurtide is a small molecule used in the treatment of osteosarcoma. It targets the nucleotide-binding oligomerization domain-containing protein 2.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Mifamurtide arm |
|---|---|
| Also known as | Methotrexate, Cisplatinum, doxorubicin, ifosfamide, mifamurtide |
| Sponsor | Italian Sarcoma Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (PHASE2)
- ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mifamurtide arm CI brief — competitive landscape report
- Mifamurtide arm updates RSS · CI watch RSS
- Italian Sarcoma Group portfolio CI
Frequently asked questions about Mifamurtide arm
What is Mifamurtide arm?
Who makes Mifamurtide arm?
Is Mifamurtide arm also known as anything else?
What development phase is Mifamurtide arm in?
Related
- Manufacturer: Italian Sarcoma Group — full pipeline
- Also known as: Methotrexate, Cisplatinum, doxorubicin, ifosfamide, mifamurtide
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing